Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.

Journal of managed care pharmacy : JMCP

Volumn 11, Issue 8, 2005, Pages 687-694

  Malone, Daniel C ^a   Tran, Tram T ^a   Poordad, F Fred ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG EFFECT; ECONOMICS; FEMALE; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; METHODOLOGY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MULTICENTER STUDIES; POLYETHYLENE GLYCOLS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745696443     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2005.11.8.687     Document Type: Article

References (0)